SUMMARY A technique using indirect immunoperoxidase antibody was developed for the detection of specific serum IgA antibody to Epstein-Barr virus capsid antigen and early antigen. The IgA technique was compared with an immunofluorescence antibody method. Epstein-Barr virus IgA antibody against viral capsid antigen was detected in all nine patients with Epstein-Barr virus associated undifferentiated nasopharyngeal carcinoma, in 13 (72.2%) of 18 patients with infectious mononucleosis, in 21 (28 3%) of 74 patients with acute lymphoblastic leukaemia, and in six (20%) of 30 patients who had recently had kidney transplants. Epstein-Barr virus IgA antibody against viral capsid antigen was also detected in four (10%) of 40 healthy subjects, but it was not found in any of 20 cord blood samples. Epstein-Barr virus IgA antibody to early antigen was detected in six (66 6%) patients with nasopharyngeal carcinoma and in two (2-7%) patients with acute lymphoblastic leukaemia. The immunoperoxidase assay for Epstein-Barr virus specific IgA was simple, reliable, and rapid and cor-related well (r = 0.94) with the immunofluorescence antibody technique.
SUMMARY A technique using indirect immunoperoxidase antibody was developed for the detection of specific serum IgA antibody to Epstein-Barr virus capsid antigen and early antigen. The IgA technique was compared with an immunofluorescence antibody method. Epstein-Barr virus IgA antibody against viral capsid antigen was detected in all nine patients with Epstein-Barr virus associated undifferentiated nasopharyngeal carcinoma, in 13 (72.2%) of 18 patients with infectious mononucleosis, in 21 (28 3%) of 74 patients with acute lymphoblastic leukaemia, and in six (20%) of 30 patients who had recently had kidney transplants. Epstein-Barr virus IgA antibody against viral capsid antigen was also detected in four (10%) of 40 healthy subjects, but it was not found in any of 20 cord blood samples. Epstein-Barr virus IgA antibody to early antigen was detected in six (66 6%) patients with nasopharyngeal carcinoma and in two (2-7%) samples randomly collected at delivery.
The immunoperoxidase and immunofluorescence titres of the positive sera from patients tested for Epstein-Barr virus specific IgA antibody to viral capsid antigen and early antigen are compared in the The presence of Epstein-Barr virus specific IgA antibody in serum is a characteristic feature of nasopharyngeal carcinoma. 12 13 Epstein-Barr virus specific serum IgA has also been reported with varying frequency in patients with infectious mononucleosis. '4-16 Twenty per cent of kidney transplant patients and 28-3% of patients with acute lymphoblastic Cevenini, Donati, Rumpianesi, Moroni, Paolucci leukaemia were also positive for viral capsid antigen IgA, with geometric mean titres of 11-7 and 13.7 respectively. It has already been established that transplant patients'" as well as patients with neoplastic diseases, including leukaemia,'8 often reactivate Epstein-Barr virus. The patients with acute lymphoblastic leukaemia and the kidney transplant patients whom we studied did not have a primary Epstein-Barr virus infection, but probably had a reactivation of an endogenous virus or an exogenous reinfection. In fact, the patients with acute lymphoblastic leukaemia and the kidney transplant patients who were positive for IgA to viral capsid antigen were also early antigen IgG and viral capsid antigen IgG positive. On the other hand they did not have viral capsid antigen IgM or heterophile antibody in their serum (unpublished data). This means that an endogenous reactivated Epstein-Barr virus or an exogenous reinfection or both, in cases other than nasopharyngeal carcinoma, may stimulate the production of IgA antibody to viral capsid antigen. Among healthy Epstein-Barr virus seropositive children, 15% had IgA antibody to viral capsid antigen in association with IgG to early antigen. The presence of IgA to viral capsid antigen may reflect, in these cases, a reactivated Epstein-Barr virus infection, since the children were viral capsid antigen IgM negative. IgA antibody to early antigen was detected in 66-6% of patients with nasopharyngeal carcinoma, in agreement with data previously reported by others'9 using immunofluorescence, and in only two (2 7%) patients with acute lymphoblastic leukaemia.
The results obtained in this study using the immunoperoxidase technique confirm that the detection of IgA antibody to viral capsid antigen may be used as a test in the serology of infectious mononucleosis, since 72-86% of the patients with the disease have IgA to viral capsid antigen. In addition, IgA antibody to viral capsid antigen may be, to some extent, a marker of an active Epstein-Barr virus infection, either primary (that is, infectious mononucleosis) or reactivated, as seen in patients with acute lymphoblastic leukaemia and in kidney transplant patients.
The immunoperoxidase assay technique for Epstein-Barr virus IgA antibody to viral capsid antigen and early antigen was simple and rapid to perform, and correlated well with the immunofluorescence assay (r = 0 94). Antigen can be stored frozen for long periods, which makes it easily available for diagnostic laboratories. Some advantages of the immunoperoxidase technique over immunofluorescence are that permanent slides are produced and expensive fluorescence microscopes are not required.
